Asset Details
Do you wish to reserve the book?
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Do you wish to request the book?
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
2013
Overview
Patients who have colorectal cancer with
RAS
mutations in exon 2 are unlikely to respond to EGFR blockers. A retrospective analysis of tumors containing other, less common
RAS
mutations confirms that any
RAS
mutation is associated with EGFR resistance.
KRAS
mutation is an established predictive biomarker of resistance to anti–epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer.
1
–
4
Specifically, patients with
KRAS
mutations in exon 2 do not have a response to anti-EGFR therapy and may have inferior outcomes if this therapy is combined with an oxaliplatin-containing chemotherapy regimen.
2
,
5
More accurate selection of patients according to the genetic status of the tumor may improve the benefit–risk profile of anti-EGFR therapy.
Activating mutations in
RAS
(
KRAS
or
NRAS
) in addition to
KRAS
mutations in exon 2 have been suggested as negative predictive biomarkers . . .
Publisher
Massachusetts Medical Society
Subject
/ Antibodies, Monoclonal - therapeutic use
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Colorectal Neoplasms - drug therapy
/ Colorectal Neoplasms - genetics
/ Colorectal Neoplasms - pathology
/ DNA
/ Epidermal growth factor receptors
/ Fluorouracil - therapeutic use
/ GTP Phosphohydrolases - genetics
/ Humans
/ Leucovorin - therapeutic use
/ Membrane Proteins - genetics
/ Mutation
/ Organoplatinum Compounds - therapeutic use
/ Patients
/ Proto-Oncogene Proteins - genetics
/ Proto-Oncogene Proteins B-raf - genetics
/ Proto-Oncogene Proteins p21(ras)
/ Receptor, Epidermal Growth Factor - antagonists & inhibitors
/ Survival
/ Tumors
